Global Venous Thromboembolism

Venous Thromboembolism Comprehensive Study by Type (Pneumatic Compression Sleeves (Upper, Lower), Inferior Vena Cava Filters (Permanent, Retrievable), Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices, Catheter-Directed Thrombolysis (CDT) Devices, Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient), Ype III), Application (Hospitals, Ambulatory Surgical Centers, Others), Indication (Deep Venous Thrombosis, Pulmonary Embolism), End User (Geriatric, Adult, Pediatric) Players and Region - Global Market Outlook to 2026

Venous Thromboembolism Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Venous thromboembolism (VTE) is a disease in which a blood clot arises in the deep veins of the leg, groyne, or arm (also known as DVT) and passes into the circulation, eventually lodging in the lungs (known as pulmonary embolism, PE). Deep Vein Thrombosis and Pulmonary Embolism (DVT/PE) are severe but preventable medical complications that are often underdiagnosed. VTE is a major cause of death and injury around the world. Furthermore, one-third to one-half of patients who have a DVT will have long-term problems as a result of the clot's disruption to the vein's valves, known as post-thrombotic syndrome (PTS).

Segment Analysis
AMA Research have segmented the market of Global Venous Thromboembolism market by Type, Application and Region.

On the basis of geography, the market of Venous Thromboembolism has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Trend
Increasing R&D on in Healthcare industry

Market Drivers
Prevalence of Blood Clot Associated Disorders, Rising Healthcare Awareness and Growth in Healthcare and Pharma Infrastructure

Opportunities
Low Penetration in Emerging Regions Particularly Asia

Restraints
  • Lack of Trained Professionals
  • Side Effects and Adverse Reactions


In addition to the aforementioned factor, Prevalence of Blood Clot Associated Disorders is expected to propel the growth of the market over the forecast period.

Competitive Landscape
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
The key Players profiled in the study are Pfizer (United States), ArjoHuntleigh AB (Sweden), Koninklijke Philips N.V. (Netherlands), BTG International Ltd. (United Kingdom), AngioDynamics (United States), Argon Medical Devices, Inc. (United States), Cardinal Health Inc. (Medtronic) (United States), Stryker Corporation (United States), DJO Global Inc. (United States), Boston Scientific Corp. (United States) and Teleflex Inc. (United States). A lot of United States players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • Pneumatic Compression Sleeves (Upper, Lower)
  • Inferior Vena Cava Filters (Permanent, Retrievable)
  • Embolectomy Balloon Catheters
  • Percutaneous Thrombectomy Devices
  • Catheter-Directed Thrombolysis (CDT) Devices
  • Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient)
  • ype III
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Indication
  • Deep Venous Thrombosis
  • Pulmonary Embolism

By End User
  • Geriatric
  • Adult
  • Pediatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Blood Clot Associated Disorders
      • 3.2.2. Rising Healthcare Awareness
      • 3.2.3. Growth in Healthcare and Pharma Infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Regional Regulatory Approval
      • 3.3.2. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Increasing R&D on in Healthcare industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Venous Thromboembolism, by Type, Application, Indication, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Venous Thromboembolism (Value)
      • 5.2.1. Global Venous Thromboembolism by: Type (Value)
        • 5.2.1.1. Pneumatic Compression Sleeves (Upper, Lower)
        • 5.2.1.2. Inferior Vena Cava Filters (Permanent, Retrievable)
        • 5.2.1.3. Embolectomy Balloon Catheters
        • 5.2.1.4. Percutaneous Thrombectomy Devices
        • 5.2.1.5. Catheter-Directed Thrombolysis (CDT) Devices
        • 5.2.1.6. Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient)
        • 5.2.1.7. Ype III
      • 5.2.2. Global Venous Thromboembolism by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Others
      • 5.2.3. Global Venous Thromboembolism by: Indication (Value)
        • 5.2.3.1. Deep Venous Thrombosis
        • 5.2.3.2. Pulmonary Embolism
      • 5.2.4. Global Venous Thromboembolism by: End User (Value)
        • 5.2.4.1. Geriatric
        • 5.2.4.2. Adult
        • 5.2.4.3. Pediatric
      • 5.2.5. Global Venous Thromboembolism Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Venous Thromboembolism: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ArjoHuntleigh AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Koninklijke Philips N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BTG International Ltd. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AngioDynamics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Argon Medical Devices, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cardinal Health Inc. (Medtronic) (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Stryker Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DJO Global Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boston Scientific Corp. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teleflex Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Venous Thromboembolism Sale, by Type, Application, Indication, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Venous Thromboembolism (Value)
      • 7.2.1. Global Venous Thromboembolism by: Type (Value)
        • 7.2.1.1. Pneumatic Compression Sleeves (Upper, Lower)
        • 7.2.1.2. Inferior Vena Cava Filters (Permanent, Retrievable)
        • 7.2.1.3. Embolectomy Balloon Catheters
        • 7.2.1.4. Percutaneous Thrombectomy Devices
        • 7.2.1.5. Catheter-Directed Thrombolysis (CDT) Devices
        • 7.2.1.6. Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient)
        • 7.2.1.7. Ype III
      • 7.2.2. Global Venous Thromboembolism by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Others
      • 7.2.3. Global Venous Thromboembolism by: Indication (Value)
        • 7.2.3.1. Deep Venous Thrombosis
        • 7.2.3.2. Pulmonary Embolism
      • 7.2.4. Global Venous Thromboembolism by: End User (Value)
        • 7.2.4.1. Geriatric
        • 7.2.4.2. Adult
        • 7.2.4.3. Pediatric
      • 7.2.5. Global Venous Thromboembolism Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Venous Thromboembolism: by Type(USD Million)
  • Table 2. Venous Thromboembolism Pneumatic Compression Sleeves (Upper, Lower) , by Region USD Million (2015-2020)
  • Table 3. Venous Thromboembolism Inferior Vena Cava Filters (Permanent, Retrievable) , by Region USD Million (2015-2020)
  • Table 4. Venous Thromboembolism Embolectomy Balloon Catheters , by Region USD Million (2015-2020)
  • Table 5. Venous Thromboembolism Percutaneous Thrombectomy Devices , by Region USD Million (2015-2020)
  • Table 6. Venous Thromboembolism Catheter-Directed Thrombolysis (CDT) Devices , by Region USD Million (2015-2020)
  • Table 7. Venous Thromboembolism Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient) , by Region USD Million (2015-2020)
  • Table 8. Venous Thromboembolism Ype III , by Region USD Million (2015-2020)
  • Table 9. Venous Thromboembolism: by Application(USD Million)
  • Table 10. Venous Thromboembolism Hospitals , by Region USD Million (2015-2020)
  • Table 11. Venous Thromboembolism Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 12. Venous Thromboembolism Others , by Region USD Million (2015-2020)
  • Table 13. Venous Thromboembolism: by Indication(USD Million)
  • Table 14. Venous Thromboembolism Deep Venous Thrombosis , by Region USD Million (2015-2020)
  • Table 15. Venous Thromboembolism Pulmonary Embolism , by Region USD Million (2015-2020)
  • Table 16. Venous Thromboembolism: by End User(USD Million)
  • Table 17. Venous Thromboembolism Geriatric , by Region USD Million (2015-2020)
  • Table 18. Venous Thromboembolism Adult , by Region USD Million (2015-2020)
  • Table 19. Venous Thromboembolism Pediatric , by Region USD Million (2015-2020)
  • Table 20. South America Venous Thromboembolism, by Country USD Million (2015-2020)
  • Table 21. South America Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 22. South America Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 23. South America Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 24. South America Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 25. Brazil Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 26. Brazil Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 27. Brazil Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 28. Brazil Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 29. Argentina Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 30. Argentina Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 31. Argentina Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 32. Argentina Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 33. Rest of South America Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 36. Rest of South America Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 37. Asia Pacific Venous Thromboembolism, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 41. Asia Pacific Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 42. China Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 43. China Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 44. China Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 45. China Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 46. Japan Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 47. Japan Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 48. Japan Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 49. Japan Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 50. India Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 51. India Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 52. India Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 53. India Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 54. South Korea Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 55. South Korea Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 56. South Korea Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 57. South Korea Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 58. Taiwan Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 59. Taiwan Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 60. Taiwan Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 61. Taiwan Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 62. Australia Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 63. Australia Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 64. Australia Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 65. Australia Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 70. Europe Venous Thromboembolism, by Country USD Million (2015-2020)
  • Table 71. Europe Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 72. Europe Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 73. Europe Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 74. Europe Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 75. Germany Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 76. Germany Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 77. Germany Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 78. Germany Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 79. France Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 80. France Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 81. France Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 82. France Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 83. Italy Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 84. Italy Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 85. Italy Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 86. Italy Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 87. United Kingdom Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 90. United Kingdom Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 91. Netherlands Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 92. Netherlands Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 93. Netherlands Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 94. Netherlands Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 95. Rest of Europe Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 98. Rest of Europe Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 99. MEA Venous Thromboembolism, by Country USD Million (2015-2020)
  • Table 100. MEA Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 101. MEA Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 102. MEA Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 103. MEA Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 104. Middle East Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 105. Middle East Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 106. Middle East Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 107. Middle East Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 108. Africa Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 109. Africa Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 110. Africa Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 111. Africa Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 112. North America Venous Thromboembolism, by Country USD Million (2015-2020)
  • Table 113. North America Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 114. North America Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 115. North America Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 116. North America Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 117. United States Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 118. United States Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 119. United States Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 120. United States Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 121. Canada Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 122. Canada Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 123. Canada Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 124. Canada Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 125. Mexico Venous Thromboembolism, by Type USD Million (2015-2020)
  • Table 126. Mexico Venous Thromboembolism, by Application USD Million (2015-2020)
  • Table 127. Mexico Venous Thromboembolism, by Indication USD Million (2015-2020)
  • Table 128. Mexico Venous Thromboembolism, by End User USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Venous Thromboembolism: by Type(USD Million)
  • Table 141. Venous Thromboembolism Pneumatic Compression Sleeves (Upper, Lower) , by Region USD Million (2021-2026)
  • Table 142. Venous Thromboembolism Inferior Vena Cava Filters (Permanent, Retrievable) , by Region USD Million (2021-2026)
  • Table 143. Venous Thromboembolism Embolectomy Balloon Catheters , by Region USD Million (2021-2026)
  • Table 144. Venous Thromboembolism Percutaneous Thrombectomy Devices , by Region USD Million (2021-2026)
  • Table 145. Venous Thromboembolism Catheter-Directed Thrombolysis (CDT) Devices , by Region USD Million (2021-2026)
  • Table 146. Venous Thromboembolism Pneumatic Compression Pumps (Non-Segmented, Segmented Without Gradient, Segmented Calibrated Gradient) , by Region USD Million (2021-2026)
  • Table 147. Venous Thromboembolism Ype III , by Region USD Million (2021-2026)
  • Table 148. Venous Thromboembolism: by Application(USD Million)
  • Table 149. Venous Thromboembolism Hospitals , by Region USD Million (2021-2026)
  • Table 150. Venous Thromboembolism Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 151. Venous Thromboembolism Others , by Region USD Million (2021-2026)
  • Table 152. Venous Thromboembolism: by Indication(USD Million)
  • Table 153. Venous Thromboembolism Deep Venous Thrombosis , by Region USD Million (2021-2026)
  • Table 154. Venous Thromboembolism Pulmonary Embolism , by Region USD Million (2021-2026)
  • Table 155. Venous Thromboembolism: by End User(USD Million)
  • Table 156. Venous Thromboembolism Geriatric , by Region USD Million (2021-2026)
  • Table 157. Venous Thromboembolism Adult , by Region USD Million (2021-2026)
  • Table 158. Venous Thromboembolism Pediatric , by Region USD Million (2021-2026)
  • Table 159. South America Venous Thromboembolism, by Country USD Million (2021-2026)
  • Table 160. South America Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 161. South America Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 162. South America Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 163. South America Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 164. Brazil Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 165. Brazil Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 166. Brazil Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 167. Brazil Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 168. Argentina Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 169. Argentina Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 170. Argentina Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 171. Argentina Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 172. Rest of South America Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 175. Rest of South America Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 176. Asia Pacific Venous Thromboembolism, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 180. Asia Pacific Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 181. China Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 182. China Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 183. China Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 184. China Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 185. Japan Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 186. Japan Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 187. Japan Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 188. Japan Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 189. India Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 190. India Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 191. India Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 192. India Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 193. South Korea Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 194. South Korea Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 195. South Korea Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 196. South Korea Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 197. Taiwan Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 198. Taiwan Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 199. Taiwan Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 200. Taiwan Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 201. Australia Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 202. Australia Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 203. Australia Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 204. Australia Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 209. Europe Venous Thromboembolism, by Country USD Million (2021-2026)
  • Table 210. Europe Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 211. Europe Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 212. Europe Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 213. Europe Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 214. Germany Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 215. Germany Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 216. Germany Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 217. Germany Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 218. France Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 219. France Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 220. France Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 221. France Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 222. Italy Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 223. Italy Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 224. Italy Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 225. Italy Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 226. United Kingdom Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 229. United Kingdom Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 230. Netherlands Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 231. Netherlands Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 232. Netherlands Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 233. Netherlands Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 234. Rest of Europe Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 237. Rest of Europe Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 238. MEA Venous Thromboembolism, by Country USD Million (2021-2026)
  • Table 239. MEA Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 240. MEA Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 241. MEA Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 242. MEA Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 243. Middle East Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 244. Middle East Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 245. Middle East Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 246. Middle East Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 247. Africa Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 248. Africa Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 249. Africa Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 250. Africa Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 251. North America Venous Thromboembolism, by Country USD Million (2021-2026)
  • Table 252. North America Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 253. North America Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 254. North America Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 255. North America Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 256. United States Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 257. United States Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 258. United States Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 259. United States Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 260. Canada Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 261. Canada Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 262. Canada Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 263. Canada Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 264. Mexico Venous Thromboembolism, by Type USD Million (2021-2026)
  • Table 265. Mexico Venous Thromboembolism, by Application USD Million (2021-2026)
  • Table 266. Mexico Venous Thromboembolism, by Indication USD Million (2021-2026)
  • Table 267. Mexico Venous Thromboembolism, by End User USD Million (2021-2026)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Venous Thromboembolism: by Type USD Million (2015-2020)
  • Figure 5. Global Venous Thromboembolism: by Application USD Million (2015-2020)
  • Figure 6. Global Venous Thromboembolism: by Indication USD Million (2015-2020)
  • Figure 7. Global Venous Thromboembolism: by End User USD Million (2015-2020)
  • Figure 8. South America Venous Thromboembolism Share (%), by Country
  • Figure 9. Asia Pacific Venous Thromboembolism Share (%), by Country
  • Figure 10. Europe Venous Thromboembolism Share (%), by Country
  • Figure 11. MEA Venous Thromboembolism Share (%), by Country
  • Figure 12. North America Venous Thromboembolism Share (%), by Country
  • Figure 13. Global Venous Thromboembolism share by Players 2020 (%)
  • Figure 14. Global Venous Thromboembolism share by Players (Top 3) 2020(%)
  • Figure 15. Global Venous Thromboembolism share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2020
  • Figure 19. ArjoHuntleigh AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 20. ArjoHuntleigh AB (Sweden) Revenue: by Geography 2020
  • Figure 21. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 23. BTG International Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. BTG International Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 25. AngioDynamics (United States) Revenue, Net Income and Gross profit
  • Figure 26. AngioDynamics (United States) Revenue: by Geography 2020
  • Figure 27. Argon Medical Devices, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Argon Medical Devices, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Cardinal Health Inc. (Medtronic) (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cardinal Health Inc. (Medtronic) (United States) Revenue: by Geography 2020
  • Figure 31. Stryker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Stryker Corporation (United States) Revenue: by Geography 2020
  • Figure 33. DJO Global Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. DJO Global Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Boston Scientific Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Boston Scientific Corp. (United States) Revenue: by Geography 2020
  • Figure 37. Teleflex Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Teleflex Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Venous Thromboembolism: by Type USD Million (2021-2026)
  • Figure 40. Global Venous Thromboembolism: by Application USD Million (2021-2026)
  • Figure 41. Global Venous Thromboembolism: by Indication USD Million (2021-2026)
  • Figure 42. Global Venous Thromboembolism: by End User USD Million (2021-2026)
  • Figure 43. South America Venous Thromboembolism Share (%), by Country
  • Figure 44. Asia Pacific Venous Thromboembolism Share (%), by Country
  • Figure 45. Europe Venous Thromboembolism Share (%), by Country
  • Figure 46. MEA Venous Thromboembolism Share (%), by Country
  • Figure 47. North America Venous Thromboembolism Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • ArjoHuntleigh AB (Sweden)
  • Koninklijke Philips N.V. (Netherlands)
  • BTG International Ltd. (United Kingdom)
  • AngioDynamics (United States)
  • Argon Medical Devices, Inc. (United States)
  • Cardinal Health Inc. (Medtronic) (United States)
  • Stryker Corporation (United States)
  • DJO Global Inc. (United States)
  • Boston Scientific Corp. (United States)
  • Teleflex Inc. (United States)
Additional players considered in the study are as follows:
Sky Medical (United Kingdom) , DS Maref Co., Ltd. (South Korea)
Select User Access Type

Key Highlights of Report


Apr 2021 223 Pages 73 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Venous Thromboembolism Quantitative research analysis
Global Venous Thromboembolism Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Venous Thromboembolism Report?

Have a Query? Click Here

Other Related Reports

Vaginal Slings Comprehensive Study by Type (Tension free Vaginal Tape (TVT) Slings, Transobturator Tape (TOT) Slings, Mini-Slings and Single Incision Slings), Type of Urinary Incontinence (Stress Uri...
$ 3750
Lysosomal Storage Diseases Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers), Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), Indicat...
$ 3450
Male Infertility Comprehensive Study by Treatment (Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)), Varicocele Surgery, Medication), Test (DNA...
$ 3750
Postmenopausal Vaginal Atrophy Treatment Comprehensive Study by Type (Prasterone (Intrarosa)), Application (Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina...
$ 3650
Meningitis Diagnostic Testing Comprehensive Study by Application (Viral Meningitis, Bacterial Meningitis, Fungal Meningitis, Hib Meningitis, Others), Test Type (Latex Agglutination Tests, Lateral Flo...
$ 3650
Hemostasis Diagnostics Comprehensive Study by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems), Point-of-Care Testing Systems), Application (Hospital/Clinics, In...
$ 3750